摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-2-methylpyrrolidine L-tartrate

中文名称
——
中文别名
——
英文名称
(R)-2-methylpyrrolidine L-tartrate
英文别名
(2R)-2-methylpyrrolidin-1-ium;(2R,3R)-2,3,4-trihydroxy-4-oxobutanoate
(R)-2-methylpyrrolidine L-tartrate化学式
CAS
——
化学式
C4H6O6*C5H11N
mdl
——
分子量
235.237
InChiKey
AVAOHVDRAKDFRF-KLPPUMKISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.36
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    127
  • 氢给体数:
    5
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1-{2-[4'-(3-METHOXYPROPANE-1-SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE<br/>[FR] PROCÉDÉS UTILES POUR LA SYNTHÈSE DE LA (R)-1-{2-[4'-(3-MÉTHOXYPROPANE-1-SULFONYL)-BIPHÉNYL-4-YL]-ÉTHYL}-2-MÉTHYL-PYRROLIDINE
    申请人:ARENA PHARM INC
    公开号:WO2009128907A1
    公开(公告)日:2009-10-22
    Processes useful for making a pharmaceutically useful compound according to Formula (I), forms of such a compound, and intermediates useful in such processes are described.
    根据公式(I)制备药用化合物的有用过程,以及该化合物的形式和在这些过程中有用的中间体被描述。
  • [EN] MODULATORS OF THE HISTAMINE H3 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR H3 HISTAMINIQUE ET TRAITEMENT DE TROUBLES S'Y RAPPORTANT
    申请人:ARENA PHARM INC
    公开号:WO2014028322A1
    公开(公告)日:2014-02-20
    The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the histamine H3 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders.
    本发明涉及式(Ia)的化合物及其药用可接受的盐、溶剂和合物,这些化合物调节组胺H3受体的活性。本发明的化合物和药物组合物用于治疗组胺H3相关疾病的方法。
  • [EN] MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR D'HISTAMINE H3 UTILES POUR LE TRAITEMENT D'AFFECTIONS QUI LUI SONT ASSOCIÉES
    申请人:ARENA PHARM INC
    公开号:WO2009105206A1
    公开(公告)日:2009-08-27
    Amide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as excessive daytime sleepiness, narcolepsy, shift-work sleep disorder, drowsiness as a side effect from a medication, maintenance of vigilance to aid in the completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease, pain and the like.
    Formula (Ia)的酰胺衍生物及其药物组合物,可调节组胺H3受体的活性。本发明的化合物及其药物组合物用于治疗组胺H3相关疾病的方法,如认知障碍、癫痫、脑外伤、抑郁症、肥胖症、睡眠和觉醒障碍(如白天过度嗜睡、嗜睡症、倒班工作睡眠障碍、药物副作用引起的嗜睡、保持警觉以帮助完成任务等)、猝倒、嗜睡症、嗜睡综合征、时差反应、睡眠呼吸暂停等、注意力缺陷多动障碍(ADHD)、精神分裂症、过敏、上呼吸道过敏反应、过敏性鼻炎、鼻塞、痴呆症、阿尔茨海默病、疼痛等。
  • Fused bicyclic-substituted amines as histamine-3 receptor ligands
    申请人:——
    公开号:US20040248899A1
    公开(公告)日:2004-12-09
    Compounds of formula (I) 1 are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands and methods for using such compounds and compositions.
    公式(I)1的化合物在治疗由组胺-3受体配体预防或改善的状况或疾病中是有用的。还公开了包含组胺-3受体配体的药物组合物以及使用这些化合物和组合物的方法。
  • [EN] METHODS AND COMPOUNDS USEFUL IN TREATING PRURITUS, AND METHODS FOR IDENTIFYING SUCH COMPOUNDS<br/>[FR] MÉTHODES ET COMPOSÉS UTILES POUR TRAITER LE PRURIT, ET PROCÉDÉS D'IDENTIFICATION DESDITS COMPOSÉS
    申请人:ARENA PHARM INC
    公开号:WO2013151982A1
    公开(公告)日:2013-10-10
    The present invention relates to methods of using histamine 3 receptor (H3R) antagonists to treat pruritus or itch in an individual and methods for using H3R to screen for compounds capable of treating pruritus in an individual and methods for using pruritus/itch model systems for screening H3R antagonists for their usefulness in treating pruritus.
    本发明涉及使用组胺3受体(H3R)拮抗剂治疗个体的瘙痒或瘙痒的方法,以及使用H3R筛选能够治疗个体瘙痒的化合物的方法,以及使用瘙痒/瘙痒模型系统筛选H3R拮抗剂以评估其在治疗瘙痒方面的有效性的方法。
查看更多